Hematologic Malignancy
Aggressive NK-Cell Leukemia
CI-CAN-00001752Explore in graph →
Hematologic4 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001752Explore in graph →
Clinical trials
10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT05863234 | Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia | recruiting | Phase 1 / Phase 2 | 7 | Hiroshima University HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
| completed |
| Phase 1 |
| 45 |
| National Cancer Institute (NCI)NIH |
| 2 |
| Apr 29, 2014 |
| clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials